Prescient Therapeutics (ASX:PTX) Trading Up 25%

Shares of Prescient Therapeutics Ltd (ASX:PTX) were up 25% during trading on Tuesday . The company traded as high as A$0.06 ($0.04) and last traded at A$0.06 ($0.04), approximately 4,467,170 shares traded hands during trading. The stock had previously closed at A$0.04 ($0.03).

The business has a fifty day moving average price of A$0.05. The company has a market capitalization of $21.68 million and a PE ratio of -3.44.

About Prescient Therapeutics (ASX:PTX)

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors.

Recommended Story: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Prescient Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prescient Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.